Clinical trial • Phase IV • Other
Mepivacaine hydrochloride for Postoperative pain
Phase IV trial of Mepivacaine hydrochloride for Postoperative pain.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Postoperative pain
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
- Paediatric Trial
- Yes
Key dates
- Initial CTIS Submission Date
- 21-11-2023
- First CTIS Authorization Date
- 12-02-2024
Trial design
Randomised, open-label, experimental arm: locoregional analgesia + general anaesthesia; control arm: general anaesthesia alone. Phase IV trial in France.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Experimental arm: Locoregional Analgesia + general anaesthesia; Control arm: General anaesthesia alone.
- Target Sample Size
- 222
- Trial Duration For Participant
- 365
Eligibility
Recruits 222 paediatric patients.
- Vulnerable Population
- Children aged ≥5 years and <15 years 3 months are the trial population. Informed and signed consent of the patient and one of the two holders of parental authority is required; age-specific subject information and informed consent forms are provided (SIS and ICF 5-10y, SIS and ICF 10-15y) and a parent ICF is available.
Inclusion criteria
- {"criterion_text":"- Age ≥ 5 years and < 15 years and 3 month"}
- {"criterion_text":"- Indication for surgical treatment of a fracture by osteosynthesis"}
- {"criterion_text":"- Patient affiliated to the social security system"}
- {"criterion_text":"- Informed and signed consent of patient and one of the two holders of parental authority"}
- {"criterion_text":"- Conscious patient (Glasgow score =15)"}
- {"criterion_text":"- Patient can give a verbal assessment of their pain"}
Exclusion criteria
- {"criterion_text":"- Refusal to participate by one of the two holders of parental authority or by the child"}
- {"criterion_text":"- atrioventricular conduction disorders"}
- {"criterion_text":"- Sensory neurological deficit of the operated limb on preoperative examination"}
- {"criterion_text":"- Ischemia of the operated limb on preoperative examination"}
- {"criterion_text":"- Polytrauma patient"}
- {"criterion_text":"- Known allergy to Mepivacaine"}
- {"criterion_text":"- Patient included in a category 1 interventional clinical trial of analgesic therapy"}
- {"criterion_text":"- Patient on anticoagulant drugs"}
- {"criterion_text":"- Epilepsy not controlled by a treatment"}
- {"criterion_text":"- Porphyria"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Measurement of pain by a Numerical Rating Scale (NRS) 3 months after pediatric orthopedic trauma surgery","definition_or_measurement_approach":"Pain measured by Numerical Rating Scale (NRS) at 3 months after pediatric orthopedic trauma surgery."}
Secondary endpoints
- {"endpoint_text":"- Response score to DN4 neuropathic pain screening questionnaire ≥4/10 at 3, 6 and 12 months.","definition_or_measurement_approach":"DN4 neuropathic pain screening questionnaire; response defined as DN4 score ≥4/10 measured at 3, 6 and 12 months."}
- {"endpoint_text":"- 1st EN score for immediate post-operative care in the Post-Interventional Monitoring Room","definition_or_measurement_approach":"Immediate postoperative pain assessed by first Numerical Rating Scale (EN) score in the Post-Interventional Monitoring Room."}
- {"endpoint_text":"- Presence of pain assessed by numerical scale >3/10 at 6 and 12 months post-surgery","definition_or_measurement_approach":"Presence of pain defined as numerical scale score >3/10 measured at 6 and 12 months post-surgery."}
- {"endpoint_text":"- The number of patients experiencing at least one episode of nausea and one episode of vomiting in the Post-Interventional Monitoring Room.","definition_or_measurement_approach":"Count of patients with at least one episode of nausea and at least one episode of vomiting in the Post-Interventional Monitoring Room."}
- {"endpoint_text":"- Duration in minutes of monitoring in the Post-Interventional Monitoring Room","definition_or_measurement_approach":"Monitoring duration measured in minutes in the Post-Interventional Monitoring Room."}
- {"endpoint_text":"- The dose of intravenous opiates received intraoperatively, the dose of intravenous opiates titrated in the Post-Interventional Monitoring Room and the dose of opiates received in the hospital ward during the first 24 hours postoperatively.","definition_or_measurement_approach":"Quantification of opiate doses administered intraoperatively, in the Post-Interventional Monitoring Room (titrated), and in the ward during first 24 hours post-op."}
- {"endpoint_text":"- The dose of IV morphine received in the ICU.","definition_or_measurement_approach":"Dose of intravenous morphine received in the Post-Interventional Monitoring Room / ICU measured (total dose)."}
Recruitment
- Planned Sample Size
- 222
- Recruitment Window Months
- 60
- Consent Approach
- Informed and signed consent required from the patient and one of the two holders of parental authority; age-specific information and consent forms available (SIS and ICF 5-10y, SIS and ICF 10-15y) and parent ICF.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 222
France
- Earliest CTIS Part Ii Submission Date
- 10-01-2024
- Latest Decision Or Authorization Date
- 12-03-2026
- Processing Time Days
- 792
- Number Of Sites
- 1
- Number Of Participants
- 222
Sites
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- ANESTHESIE
- Contact Person Name
- Benoît LESVIER
- Contact Person Email
- benoit.lesvier@chu-nantes.fr
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire De Nantes
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Third parties
- {"country":"","full_name":"Fondation APICIL","duties_or_roles":"","organisation_type":""}
- {"country":"","full_name":"CHU Nantes - Appel d'offre interne","duties_or_roles":"","organisation_type":""}
Investigational products
- Investigational Product Name
- CARBOCAINE 10 mg/ml, solution injectable
- Active Substance
- Mepivacaine hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- Perineural use (solution for injection)
- Route
- Perineural
- Authorisation Status
- Authorised (marketing authorisation present)
- Maximum Dose
- 5 mg/kg
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.